S
SarahProcter
Guest
I have read all sorts of positive posts and articles and other opinions with regard to the recent results published by Vertex re: the initial study of VX-809 with VX-770 in patients with double delta F508 mutations. Am I the only person who finds them really disappointing? For folks with G551D, vx770 looks <b>amazing</b>, with something like a 45 point drop in the sweat test value after just a couple weeks of therapy. For the combo for patients with DD508, the numbers aren't nearly that good.<div><br></div><div>But I keep reading that it's promising and hopeful and good. What am I missing? Am I the only one who finds it disappointing?</div>